FindTrial
Sign In

Paraoxonase 1 (PON-1) polymorphisms,activity and Coronary Artery Disease (CAD)

A Case-Control study to assess the prevalence and association of different Paraoxonase 1 (PON-1) polymorphisms and its activity with Coronary Artery Disease (CAD)

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2017/08/009319
Enrollment
502
Registered
2017-08-09
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Angiographically proven Coronary Artery Disease patients Health Condition 2: I248- Other forms of acute ischemic heart disease

Interventions

None listed

Sponsors

Diamond Jubilee Society Trust King Edward Memorial Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: A)For Cases: 1. Males or females aged >=18 years. 2. Patient having any one of the following CAD with at least 50 percent occlusion of the lumen of one or more coronary arteries, as evidenced by coronary angiography, IVUS, or other methods.i.Acute coronary syndrome (STEMI / NSTEMI/ Unstable angina)ii.Chronic stable angina. 3. Patient willing to give written informed consent. B)For Controls: 1. Normal and healthy individual of either gender between 18 to 65 years, both inclusive. 2. No history of major illness in the past 6 months and should not be taking any kind of medication at least 4 weeks prior to participation in the trial. 3.The volunteer willing to abide by trial procedures and give written informed consent

Exclusion criteria

Exclusion criteria: A)For Cases: 1.Any medical or psychiatric condition which in the opinion of the investigator makes the patient an unsuitable candidate for the study 2. The participant in any other investigational study in last 4 weeks 3. History of alcohol or substance abuse within the past year For Controls: 1. Clinically significant haematological and biochemical parameters as assessed by the investigator 2. Pregnant and lactating women. 3. Volunteers having signs and symptoms of AIDS and/or advanced Hepatitis B infection.

Design outcomes

Primary

MeasureTime frame
To study the prevalence ofGln-Arg192 (Q192R) and Leu-Met55 (L55M) polymorphisms of PON-1 in normal healthy volunteers[Controls] and patients of Coronary Artery Disease (CAD) [Cases]Timepoint: 1 year—

Secondary

MeasureTime frame
To compare PON-1 activity between cases and controlsTimepoint: 1 year;To evaluate the association of PON-1 polymorphisms and CAD.Timepoint: 1 year—

Countries

India

Contacts

Public ContactDr Urmila Thatte

King Edward Memorial Hospital

charutagodbole@gmail.com9833727400

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026